1. Home
  2. KOS vs AGIO Comparison

KOS vs AGIO Comparison

Compare KOS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$2.68

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.08

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
AGIO
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
KOS
AGIO
Price
$2.68
$28.08
Analyst Decision
Hold
Buy
Analyst Count
6
8
Target Price
$1.76
$37.63
AVG Volume (30 Days)
31.3M
642.1K
Earning Date
03-02-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,288,352,000.00
$43,011,000.00
Revenue This Year
$21.14
$75.68
Revenue Next Year
N/A
$167.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$22.24
52 Week High
$3.01
$46.00

Technical Indicators

Market Signals
Indicator
KOS
AGIO
Relative Strength Index (RSI) 60.74 48.34
Support Level $1.53 $26.48
Resistance Level $2.77 $29.49
Average True Range (ATR) 0.23 0.92
MACD 0.01 -0.06
Stochastic Oscillator 69.27 48.37

Price Performance

Historical Comparison
KOS
AGIO

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: